Back to News
Market Impact: 0.42
Evommune scraps eczema drug after trial miss, shares plunge
Source: reuters.com
Healthcare & BiotechCompany Fundamentals
Evommune will discontinue development of its experimental skin-disease drug after it failed to meet the primary endpoint in a mid-stage clinical trial. Shares fell 24% in aftermarket trading, reflecting a material setback to the company’s pipeline and valuation.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly negative
Sentiment Score
-0.72
Ticker Sentiment
EVMN-0.90
More News
- Kinder Morgan, Energy Transfer and Williams could benefit from cheap natural gas
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- With earnings in rearview mirror, SpaceX-Tesla merger chatter takes center stage
- Volvo CEO Says China Market Gone, Luxury Weakness Remains
- J&J prostate cancer drug shows promising tumor responses in early trial
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Unstructured Data Search, Ask AI, and Advanced Futures Data
- Best AI Stock Research Tools for Professional Investors